Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uroosa Ibrahim

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Cureus|October 5, 2016
Persistence of a Cervical Neck Mass, Not Just the LymphomaSassine Ghanem, Mazen Zaarour, Uroosa Ibrahim, et al.
Cureus|January 30, 2018
Embryonal Rhabdomyosarcoma of the Cervix: A Rare Disease at an Uncommon AgeUroosa Ibrahim, Amina Saqib, Farhan Mohammad, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|May 6, 2024
Dynamics of cytomegalovirus-specific T-cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot studySamantha E Jacobs, Uroosa Ibrahim, Akasha Barreto Vega, et al.
British Journal of Haematology|May 2, 2023
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLDMarshall McKenna, Narendranath Epperla, Armin Ghobadi, et al.
Transplantation and Cellular Therapy|October 3, 2025
Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic TransplantationShannon R McCurdy, Scott R Solomon, Brian C Shaffer, et al.
American Journal of Hematology|January 11, 2023
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Michael A Spinner, Kevin David, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2024
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)Joshua A Hill, Michael J Martens, Jo-Anne H Young, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2024
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational StudyJoshua A Hill, Michael J Martens, Jo-Anne H Young, et al.
Blood Cancer Journal|June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Susan M Geyer, Levi Pederson, et al.
Blood Advances|September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent eraSanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Cureus|October 5, 2016
Persistence of a Cervical Neck Mass, Not Just the LymphomaSassine Ghanem, Mazen Zaarour, Uroosa Ibrahim, et al.
Cureus|January 30, 2018
Embryonal Rhabdomyosarcoma of the Cervix: A Rare Disease at an Uncommon AgeUroosa Ibrahim, Amina Saqib, Farhan Mohammad, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|May 6, 2024
Dynamics of cytomegalovirus-specific T-cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot studySamantha E Jacobs, Uroosa Ibrahim, Akasha Barreto Vega, et al.
British Journal of Haematology|May 2, 2023
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLDMarshall McKenna, Narendranath Epperla, Armin Ghobadi, et al.
Transplantation and Cellular Therapy|October 3, 2025
Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic TransplantationShannon R McCurdy, Scott R Solomon, Brian C Shaffer, et al.
American Journal of Hematology|January 11, 2023
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Michael A Spinner, Kevin David, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2024
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)Joshua A Hill, Michael J Martens, Jo-Anne H Young, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2024
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational StudyJoshua A Hill, Michael J Martens, Jo-Anne H Young, et al.
Blood Cancer Journal|June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Susan M Geyer, Levi Pederson, et al.
Blood Advances|September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent eraSanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Pageof 5